Pericarditis Pipeline Summary

DelveInsight’s, “Pericarditis Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pericarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pericarditis Disease Understanding

Pericarditis Overview

Pericarditis is the inflammation of the pericardium, the double-layered fibroelastic sac surrounding the heart, and is the most common disorder affecting this structure. It can present as acute, subacute, chronic, or recurrent disease and may be associated with complications such as pericardial effusion, cardiac tamponade, constrictive pericarditis, and effusive-constrictive pericarditis. Inflammation often leads to fluid accumulation within the pericardial sac, which can become hemodynamically significant, causing impaired cardiac filling and potentially life-threatening cardiac tamponade. Based on the nature of the inflammatory exudate, pericarditis is classified as serous, fibrinous, purulent, caseous, or hemorrhagic, with each type reflecting distinct underlying etiologies. In some cases, persistent inflammation may result in pericardial thickening and progression to constrictive or effusive-constrictive pericarditis. Recent guidelines emphasize that pericarditis and myocarditis frequently coexist as part of an inflammatory myopericardial syndrome (IMPS), recognizing a continuum of myocardial and pericardial inflammation. Patients with pericarditis and elevated cardiac biomarkers are classified as having myopericarditis, while those with additional ventricular dysfunction are diagnosed with perimyocarditis; severe myocardial involvement with heart failure, shock, or significant arrhythmias is considered complicated myocarditis. Although myocardial inflammation accompanies approximately 15% of pericarditis cases, pericarditis remains a distinct clinical entity and the primary focus of diagnosis and management.

Pericarditis may result from infectious, noninfectious, or secondary causes, although most cases are idiopathic and presumed to be viral. Viral infections are the most common cause, while bacterial infections, particularly tuberculosis in endemic regions, as well as fungal and parasitic pathogens, are less frequent. Noninfectious causes include malignancies, autoimmune disorders, and metabolic conditions. It can also occur following trauma, myocardial infarction, cardiac surgery, certain medications, immune checkpoint inhibitors, and, rarely, mRNA COVID-19 vaccination. Other uncommon causes include infiltrative disorders such as amyloidosis and sarcoidosis. Despite its diverse etiologies, most cases remain idiopathic. Recurrent pericarditis is increasingly recognized as an IL-1–mediated autoinflammatory condition, providing the rationale for targeted therapies such as rilonacept.

The pericardium is a fibroelastic sac that anchors the heart, protects it from external infections, and supports normal cardiac function, although it is not essential for survival, as individuals with congenital absence of the pericardium can remain asymptomatic with normal cardiac function. Acute pericarditis is believed to result from inflammasome activation, triggering inflammatory cytokines such as IL-1ß, while persistent immune dysregulation may lead to recurrent disease. The richly innervated parietal pericardium makes inflammation highly painful, explaining why chest pain is the predominant symptom of acute pericarditis. Pericardial inflammation can also cause fluid accumulation, and the clinical impact depends more on the rate of fluid buildup than its volume, with rapid accumulation potentially causing life-threatening cardiac tamponade, whereas slow accumulation may remain asymptomatic until significant compression develops.

The pericardium is a fibroelastic sac that anchors the heart, protects it from external infections, and supports normal cardiac function, although it is not essential for survival, as individuals with congenital absence of the pericardium can remain asymptomatic with normal cardiac function. Acute pericarditis is believed to result from inflammasome activation, triggering inflammatory cytokines such as IL-1ß, while persistent immune dysregulation may lead to recurrent disease. The richly innervated parietal pericardium makes inflammation highly painful, explaining why chest pain is the predominant symptom of acute pericarditis. Pericardial inflammation can also cause fluid accumulation, and the clinical impact depends more on the rate of fluid buildup than its volume, with rapid accumulation potentially causing life-threatening cardiac tamponade, whereas slow accumulation may remain asymptomatic until significant compression develops.

The diagnosis of acute pericarditis begins with excluding other life-threatening causes of chest pain, such as acute coronary syndrome, aortic dissection, myocarditis, and pulmonary embolism. Initial evaluation includes history, physical examination, ECG, echocardiography, chest X-ray, and laboratory tests, including inflammatory markers and cardiac troponins. Diagnosis is supported by characteristic chest pain, a pericardial friction rub, typical ECG changes, elevated inflammatory markers, pericardial effusion, or imaging evidence of pericardial inflammation. Echocardiography is the primary imaging modality, while cardiac MRI and CT are used when the diagnosis is uncertain or myocardial involvement is suspected. Pericardiocentesis is indicated for cardiac tamponade and selected cases with suspected infectious, malignant, or large pericardial effusions, whereas additional diagnostic tests are guided by the suspected underlying cause.

Management of acute pericarditis focuses on treating the underlying cause while relieving inflammation and preventing recurrence. Most cases are idiopathic and can be managed on an outpatient basis with activity restriction and first-line therapy comprising high-dose nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin combined with colchicine, which significantly reduces symptom persistence and recurrence. Corticosteroids are reserved for patients who cannot tolerate or do not respond to first-line therapy, as they are associated with a higher risk of recurrence. Patients with high-risk features, including fever, large pericardial effusion, cardiac tamponade, immunosuppression, or myopericarditis, should be hospitalized for further evaluation and management. In patients with persistent inflammatory disease refractory to conventional therapy, IL-1 inhibitors such as rilonacept and anakinra have emerged as effective targeted treatments. Recurrent pericarditis is typically managed with prolonged colchicine therapy, while corticosteroid-dependent or refractory cases may require immunosuppressive agents or IL-1 inhibitors. Pericardiectomy is reserved as a last-line option for patients with severe, treatment-resistant disease.

"Pericarditis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pericarditis pipeline landscape is provided which includes the disease overview and Pericarditis treatment guidelines. The assessment part of the report embraces, in depth Pericarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pericarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pericarditis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pericarditis R&D. The therapies under development are focused on novel approaches to treat/improve Pericarditis.

Pericarditis Emerging Drugs Chapters

This segment of the Pericarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pericarditis Emerging Drugs

CardiolRx: Cardiol Therapeutics

CardiolRx™ is an investigational oral cannabidiol formulation being developed by Cardiol Therapeutics for the treatment of recurrent pericarditis. The therapy is designed to reduce inflammation by inhibiting activation of the NLRP3 inflammasome and other pro-inflammatory signaling pathways implicated in pericardial inflammation and fibrosis. CardiolRx has received U.S. FDA Orphan Drug Designation for the treatment of pericarditis and has demonstrated a favorable safety and tolerability profile in Phase I studies. In the Phase II MAvERIC-Pilot trial, the therapy produced meaningful reductions in pericarditis-related pain, normalized inflammatory markers in most patients with elevated C-reactive protein, and supported corticosteroid tapering in eligible patients. Based on these encouraging findings, Cardiol Therapeutics has advanced CardiolRx into the pivotal Phase III MAVERIC trial to evaluate its efficacy in preventing recurrent pericarditis in patients at high risk of relapse and to support potential regulatory approval.

Further product details are provided in the report...

Pericarditis Therapeutic Assessment

This segment of the report provides insights about the different Pericarditis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pericarditis

There are approx. 3+ key companies which are developing the therapies for Pericarditis. The companies which have their Pericarditis drug candidates in the most advanced stage, i.e. Phase III include, Cardiol Therapeutics.

Pericarditis Pipeline Drug Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Pericarditis Drugs Route of Administration

Pericarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Pericarditis Drugs Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Pericarditis Pipeline Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pericarditis Pipeline Development Activities

The Pericarditis Pipeline report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Pericarditis therapeutic drugs key players involved in developing key drugs.

Pericarditis Clinical Trials and Development Activities

The Pericarditis clinical trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pericarditis drugs.

Pericarditis Pipeline Report Insights

Pericarditis Pipeline Analysis
Pericarditis Therapeutic Assessment
Pericarditis Unmet Needs
Impact of Pericarditis Drugs

Pericarditis Pipeline Report Assessment

Pericarditis Pipeline Product Profiles
Pericarditis Therapeutic Assessment
Pericarditis Pipeline Assessment
Inactive Pericarditis drugs assessment
Pericarditis Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pericarditis drugs?
How many Pericarditis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pericarditis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pericarditis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pericarditis and their status?
What are the key designations that have been granted to the emerging drugs?